ProMIS Neurosciences Reports Low Side Effect Rates in Alzheimer Trial

By Adam Feuerstein · STAT News · 2026-07-28

STAT News reports that preliminary data for a new amyloid-targeting drug from ProMIS Neurosciences suggests a safer profile than current market leaders. Early clinical results showed a total ARIA rate of 4.4% across the study group, which includes both patients on the active drug

STAT News reports that preliminary data for a new amyloid-targeting drug from ProMIS Neurosciences suggests a safer profile than current market leaders. Early clinical results showed a total ARIA rate of 4.4% across the study group, which includes both patients on the active drug